Cosciens BiopharmaCSCIF +4.52%60 Days Inventory is 100.25 as of Mar. 2026, which is 1% above its 10-year median of 99.04. GuruFocus rates CSCIF with a GF Score™ of 60/100 and a GF Value™ of $2.36 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 640 Biotechnology companies, Cosciens Biopharma ranks better than 64.22% on this metric.
The historical rank and industry rank for Cosciens Biopharma's Days Inventory or its related term are showing as below:
CSCIF'
s Days Inventory Range Over the Past 10 Years
Min: 33.48 Med: 99.04 Max: 295.64
Current: 127.77
During the past 13 years, Cosciens Biopharma's highest Days Inventory was 295.64. The lowest was 33.48. And the median was 99.04.
CSCIF's Days Inventory is ranked better than 64.22% of 640
companies
in the Biotechnology industry
Industry Median: 184.145
vs CSCIF: 127.77
Cosciens Biopharma's Days Inventory
declined
from Mar. 2025 (230.63) to Mar. 2026 (100.25).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Cosciens Biopharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.91.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cosciens Biopharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.64.
Cosciens Biopharma (OTCPK:CSCIF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Cosciens Biopharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cosciens Biopharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Cosciens Biopharma Days Inventory Related Terms
Cosciens Biopharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a Days Inventory of 100.25 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cosciens Biopharma and its competitors. This is near median its historical median of 99.04. Over the past decade, Cosciens Biopharma's Days Inventory has ranged from 33.48 to 295.64. According to the industry distribution chart, Cosciens Biopharma ranks #229 out of 640 companies in the Biotechnology industry, placing it in the top 35.8%.
Is Cosciens Biopharma's Days Inventory too high?
Cosciens Biopharma's current Days Inventory of 100.25 is near median its 10-year median of 99.04. Over the past 10 years, this metric has ranged from a low of 33.48 to a high of 295.64. The Biotechnology industry median Days Inventory is 184.15. Cosciens Biopharma's value of 100.25 is 45.6% below this industry median. Based on the distribution chart, Cosciens Biopharma ranks #229 out of 640 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #229 out of 640 companies for Days Inventory. This puts Cosciens Biopharma in the upper half of its industry. The industry median Days Inventory is 184.15. Cosciens Biopharma's value of 100.25 is 45.6% below this benchmark. Historically, Cosciens Biopharma's own Days Inventory has ranged from 33.48 to 295.64 over the past decade. While the company's 10-year median is 99.04 vs. the industry median of 184.15, Cosciens Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.15, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Days Inventory of 100.25 is 45.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median Days Inventory is 184.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Days Inventory is 100.25, which is near median its own 10-year median of 99.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.36, compared to a current price of $2.08 — trading 11.9% below its estimated fair value. The current Days Inventory is 100.25, which is near median its 10-year median of 99.04 and 45.6% below the Biotechnology industry median of 184.15. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Days Inventory is 100.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $2.08 is trading 11.9% below its estimated GF Value™ of $2.36.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Days Inventory: 100.25 (near median its 10-year median of 99.04)
GF Value™: $2.36 vs. price of $2.08 (11.9% below fair value)
Industry Position: 45.6% below the Biotechnology median (#229 of 640)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score
Get the complete analysis for CSCIF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
